Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Summary of Significant Accounting Policies (Details) [Line Items]
Research and development expenses (in Dollars)	$ 19,400,000	$ 40,000,000
Amortized straight line basis over period	8 years
Patents term	20 years
Non-Hodgkin Lymphoma [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Amortized straight line basis over period	12 years